@article{oai:u-ryukyu.repo.nii.ac.jp:02020133,
 author = {Miyagi, Riko and Nakachi, Sawako and Tamaki, Yasutaro and Doi, Mototsugu and Nakajima, Tomo and Tomori, Shohei and Hanashiro, Taeko and Tamaki, Keita and Morichika, Kazuho and Nishi, Yukiko and Morishima, Satoko and Fukushima, Takuya and Masuzaki, Hiroaki},
 issue = {1},
 journal = {Modern Rheumatology Case Reports},
 month = {Aug},
 note = {Clinically amyopathic dermatomyositis (CADM) lacks muscle symptoms, associated with rapidly progressive interstitial lung disease. Anti-melanoma differentiation-associated gene 5 (MDA-5) antibody has been identified as a disease-labelling autoantibody. We report two cases of CADM manifested after the allogeneic haematopoietic stem cell transplantation (allo-HSCT)—Case 1: a 56-year-old man with acute leukaemia received the allo-HSCT and Case 2: a 45-year-old female patient with lymphoma received the allo-HSCT. She received donor lymphocyte infusion because of a post-transplant relapse. After allo-HSCT or donor lymphocyte infusion, Gottron papules emerged, and both patients were diagnosed as CADM based on dermatological findings coupled with the positivity of anti-MDA-5 antibody, accompanied by interstitial shadows consistent with ILD on chest computed tomography. Case 2 was initially diagnosed as a kind of chronic graft versus host disease. Their symptoms were improved by the combination of immunosuppressive agents with a concomitant decrease in anti-MDA-5 antibody levels. For Case 2, rituximab was subsequently started for relapse of lymphoma, resulting in a substantial decrease in the level of anti-MDA-5 antibody and improvement in rash and ILD. Our cases raise a possibility that CADM emerges after the HSCT, highlighting the importance of early diagnosis to avoid fated progression into ILD.},
 pages = {102--107},
 title = {Clinically amyopathic dermatomyositis manifested after  the allogeneic haematopoietic stem cell transplantation:  Case presentation and literature review},
 volume = {7},
 year = {2022}
}